New delivery method boosts efficiency of CRISPR genome-editing system
The genome-editing technique known as CRISPR allows scientists to clip a specific DNA sequence and replace it with a new one, offering the potential to cure diseases caused by defective genes. For this potential to be realized, however, scientists must find a way to safely deliver the CRISPR machinery and a corrected copy of the DNA into the diseased cells.
MIT researchers have now developed a way to deliver the CRISPR genome repair components more efficiently than previously possible, and they also believe it may be safer for human use. In a study of mice, they found that they could correct the mutated gene that causes a rare liver disorder, in 6 percent of liver cells — enough to cure the mice of the disease, known as tyrosinemia.
“This finding really excites us because it makes us think that this is a gene repair system that could be used to treat a range of diseases — not just tyrosinemia but others as well,” says Daniel Anderson, associate professor in MIT’s Department of Chemical Engineering and a member of MIT’s Koch Institute for Integrative Cancer Research and Institute for Medical Engineering and Science (IMES).
Anderson is one of the senior authors of a paper describing the findings in the Feb. 1 issue of Nature Biotechnology. Wen Xue, an assistant professor in molecular medicine at the University of Massachusetts Medical School, is also a senior author. The paper’s lead author is Hao Yin, a research scientist at the Koch Institute.
Find and replace
The CRISPR system relies on cellular machinery that bacteria use to defend themselves from viral infection. Researchers have previously harnessed this system to create gene-editing complexes composed of a DNA-cutting enzyme called Cas9 and a short RNA that guides the enzyme to a specific area of the genome, directing Cas9 where to make its cut.
When Cas9 and the short guide RNA targeting a disease gene are delivered into cells, a specific cut is made in the genome, and the cells’ DNA repair processes glue the cut back together, often deleting a small portion of the genome. However, if a corrected copy of the gene is also delivered when the cut is made, the DNA repair can lead to correction of the disease gene, permanently repairing the genome.
In 2014, Anderson and colleagues described the first use of CRISPR to repair a disease gene in an adult animal. In that study, they were able to cure tyrosinemia in mice. However, delivery of the genetic components required a high-pressure injection, a method that can also cause some damage to the liver.
“That was the first demonstration of using CRISPR/Cas9 to do genetic repair in an adult animal,” Anderson says. “We were excited by this demonstration but wanted to find a way to develop a drug form of the repair machinery that would be both safer and more efficient.”
The researchers also wanted to boost the percentage of cells that had the defective gene replaced. In the previous study, about one in 250 liver cells were repaired, which was enough to successfully treat tyrosinemia. However, for many other diseases, a higher percentage of repair would be needed to provide a therapeutic effect.
In the new study, Anderson and colleagues developed a combined nanoparticle and viral delivery system to deliver the CRISPR repair machinery. First, they created a nanoparticle from lipids and messenger RNA (mRNA) that encoded the Cas9 enzyme. The other two components — the RNA guide strand and the DNA for the corrected gene — were embedded into a reprogrammed viral particle based on an adeno-associated virus (AAV).
The researchers first injected the virus about a week before the lipid nanoparticles, giving the liver cells time to begin producing the RNA guide strand and the DNA template. When the nanoparticles carrying the Cas9 mRNA strand were injected, the cells began producing the Cas9 protein, but only for a few days because the mRNA eventually degraded. This is long enough to perform gene repair, but prevents cas9 from lingering in the cells and potentially disrupting other parts of the cells’ genome.
“There’s some concern that if you had Cas9 in your cells for too long of a period of time, it might cause some genomic instability,” Anderson says. “We think the use of the mRNA nanoparticle provides an additional level of safety by making sure the enzyme is not present for too long a period of time.”
High accuracy
With this method, about one in 16 cells had the gene corrected, a 15-fold improvement over the 2014 study. The researchers also found that this approach generated less off-target DNA cutting than methods in which the Cas9 gene is integrated into a cell’s genome.
“We did a genome-scale analysis and we have a very high level of on-target effects but almost no off-target effects,” Yin says.
“This is quite a promising development,” says Terence Flotte, dean of the University of Massachusetts Medical School, who was not part of the research team. “This combination of two different delivery modalities solves a number of hurdles that would otherwise make it difficult to do a gene correction in hepatocytes.”
Read more: Curing disease by repairing faulty genes
The Latest on: CRISPR
[google_news title=”” keyword=”CRISPR” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: CRISPR
- CRISPR Therapeutics AG Reports Q1 2024 Earnings: Misses Analyst Net Income Forecaston May 10, 2024 at 9:42 am
On May 8, 2024, CRISPR Therapeutics AG ( NASDAQ:CRSP) disclosed its first quarter financial results for 2024, revealing insights into its operational achievements and financial health. The company's ...
- Team develops efficient host-vector system for a model archaeon by solving CRISPR-based host-plasmid conflicton May 10, 2024 at 8:25 am
A research group has constructed versatile genetic tools for Saccharolobus islandicus REY15A, one of the very few archaeal models for archaea biology and CRISPR biology research.
- CRISPR edits fail to cure HIV patients in early teston May 10, 2024 at 6:40 am
Excision BioTherapeutics reported Friday that an early trial failed to cure HIV patients, but the company plans to try again with a more efficient editing treatment.
- Buy Rating Affirmed for Editas Medicine Amid Promising CRISPR Pipeline and Growth Potentialon May 10, 2024 at 12:53 am
The forward-looking perspective suggests significant potential catalysts in the second half of the year, particularly regarding their leading CRISPR gene editing candidate, reni-cel. With the stock ...
- Buy Rating Affirmed for Crispr Therapeutics AG on Strong Pipeline and Financial Healthon May 9, 2024 at 10:25 pm
Leerink Partners analyst Mani Foroohar has maintained their bullish stance on CRSP stock, giving a Buy rating yesterday. Mani Foroohar has ...
- CRISPR-based gene editing treatment shows promise for rare eye disorderon May 9, 2024 at 8:08 am
Researchers at Oregon Health & Science University used an experimental CRISPR-based gene editing treatment in participants with a rare eye disorder that causes low vision and blindness. The results ...
- Crispr Therapeutics Q1 Earnings: Casgevy Launch Tip Of Gene Editing Icebergon May 9, 2024 at 6:32 am
Crispr Therapeutics AG shows potential for future earnings with its gene editing therapy Casgevy, offering treatment for various diseases. Read more here.
- CRISPR gene editing trial treats inherited blindnesson May 9, 2024 at 1:24 am
Scientistse have restored vision and hearing in people born with congenital blindness or deafness in two seperate gene therapy trials A British toddler born deaf has become the first person to have ...
- CRISPR therapy restores some vision to people with blindnesson May 8, 2024 at 5:00 pm
People with an inherited condition that causes vision loss in childhood had vision improvements after treatment to replace a mutated gene.
- Clinical trial shows CRISPR gene editing has exciting potential to treat a rare form of blindnesson May 8, 2024 at 9:28 am
A newer technology makes use of gene editing with the injection of EDIT-101. It is based on the use of clustered regularly interspaced short palindromic repeats (CRISPR) coupled with the ...
via Bing News